Skip to content

Company Joins Movement as Global Contributor to Raise Awareness of  Thrombosis as an Urgent Health Problem Worldwide September 01, 2016 – Aspen, a leading global player in specialty and generic pharmaceuticals with an extensive basket of products that provide treatment for a broad spectrum of acute and chronic conditions experienced through all stages of life, today…

Read More

On 26 September, Aspen Europe organized the first International Session of the ‘Women Thrombosis Cancer’ (WTC) initiative in Barcelona, Spain. The meeting was an opportunity for the WTC Steering Committee to share its new Continuing Medical Education (CME) program with 50 leading specialists from 11 European countries and gain their expert feedback. David Pedelabat-Lartigau, Head…

Read More

This summer, Aspen Europe CIS again demonstrated its commitment to Mandela International Day (Mandela Day) by supporting local communities throughout the region – taking up the challenge issued by Former South African President Nelson Mandela to “take action, inspire change and make every day a Mandela Day”. Aspen Group has participated in this initiative for the past…

Read More

Aspen is pleased to announce that Aspen Global Incorporated (“AGI”), a wholly owned subsidiary of Aspen Holdings, has entered into an agreement with Novartis AG in term of which it will acquire the rights to Mono‐Embolex®, an injectable anti-coagulant, for a consideration of US$142.3 million. (Durban, 14 February 2015) Mono-Embolex is a heparin based anti-coagulant…

Read More

A Group of global experts in the field of thrombosis and cancer launched the Women Thrombosis Cancer (WTC) medical education initiative on 14 February 2015 at the 6th International Symposium on Women’s Health Issues in Thrombosis and Haemostasis (WHITH) in Berlin. (Berlin, Germany, 14 February 2015) “With more than 17 million women living with cancer*,…

Read More
Scroll To Top